HanchorBio Taps WuXi Biologics to Scale Fusion Protein Pipeline
Event summary
- HanchorBio partners with WuXi Biologics to accelerate development of bi- and multi-functional fusion proteins.
- WuXi Biologics will provide end-to-end biologics development and manufacturing services.
- Collaboration aims to shorten development timelines and enhance manufacturing scalability.
- HanchorBio's FBDB™ platform enables design of multi-functional fusion proteins for oncology and autoimmune diseases.
- WuXi Biologics supports 945 projects as of 2025, with 60% involving complex biologics.
The big picture
This partnership underscores the growing trend of biotech companies leveraging external CRDMOs to accelerate complex biologics development. By combining HanchorBio's innovative FBDB™ platform with WuXi Biologics' proven capabilities, the collaboration aims to address significant unmet medical needs in oncology and autoimmune diseases. The strategic move highlights the importance of execution speed and manufacturing reliability in the competitive biotech landscape.
What we're watching
- Development Speed
- How WuXi Biologics' expertise will impact HanchorBio's clinical translation timelines.
- Manufacturing Robustness
- Whether the partnership can ensure reliable, scalable production for HanchorBio's complex biologics.
- Capital Efficiency
- The pace at which HanchorBio can advance multiple clinical programs with reduced development costs.
Our editorial coverage:
Related topics